Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Fabhalta® (iptacopan) – New drug approval
December 6, 2023 - Novartis announced the FDA approval of Fabhalta (iptacopan), for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).
